97 related articles for article (PubMed ID: 10630897)
1. Protein-binding patterns of the antitumor antibiotic cryptophycin 52 as measured with a two-phase partitioning system.
Kessel D
J Chromatogr B Biomed Sci Appl; 1999 Nov; 735(1):121-6. PubMed ID: 10630897
[TBL] [Abstract][Full Text] [Related]
2. Binding of the epoxide cryptophycin analog, LY355703 to albumin and its effect on in vitro antiproliferative activity.
Schultz RM; Shih C; Wood PG; Harrison SD; Ehlhardt WJ
Oncol Rep; 1998; 5(5):1089-94. PubMed ID: 9683814
[TBL] [Abstract][Full Text] [Related]
3. Interaction of the antitumor compound cryptophycin-52 with tubulin.
Panda D; Ananthnarayan V; Larson G; Shih C; Jordan MA; Wilson L
Biochemistry; 2000 Nov; 39(46):14121-7. PubMed ID: 11087360
[TBL] [Abstract][Full Text] [Related]
4. In vitro effect of cryptophycin 52 on microtubule assembly and tubulin: molecular modeling of the mechanism of action of a new antimitotic drug.
Barbier P; Gregoire C; Devred F; Sarrazin M; Peyrot V
Biochemistry; 2001 Nov; 40(45):13510-9. PubMed ID: 11695898
[TBL] [Abstract][Full Text] [Related]
5. In vitro interactions of the aromatic retinoids Ro 10-9359 (etretinate) and Ro 10-1670 (acitretin), its main metabolite, with human serum lipoproteins and albumin.
Carillet V; Morlière P; Mazière JC; Hüppe G; Santus R; Dubertret L
Biochim Biophys Acta; 1990 Nov; 1055(2):98-101. PubMed ID: 2146977
[TBL] [Abstract][Full Text] [Related]
6. Cells in cryptophycin-induced cell-cycle arrest are susceptible to apoptosis.
Kessel D; Luo Y
Cancer Lett; 2000 Apr; 151(1):25-9. PubMed ID: 10766419
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of cryptophycin 52 using the Shi epoxidation.
Hoard DW; Moher ED; Martinelli MJ; Norman BH
Org Lett; 2002 May; 4(10):1813-5. PubMed ID: 12000306
[TBL] [Abstract][Full Text] [Related]
8. The antimalarial drug halofantrine is bound mainly to low and high density lipoproteins in human serum.
Cenni B; Meyer J; Brandt R; Betschart B
Br J Clin Pharmacol; 1995 May; 39(5):519-26. PubMed ID: 7669488
[TBL] [Abstract][Full Text] [Related]
9. A convergent approach to cryptophycin 52 analogues: synthesis and biological evaluation of a novel series of fragment a epoxides and chlorohydrins.
Al-Awar RS; Ray JE; Schultz RM; Andis SL; Kennedy JH; Moore RE; Liang J; Golakoti T; Subbaraju GV; Corbett TH
J Med Chem; 2003 Jul; 46(14):2985-3007. PubMed ID: 12825938
[TBL] [Abstract][Full Text] [Related]
10. Using capillary electrophoresis/frontal analysis to screen drugs interacting with human serum proteins.
McDonnell PA; Caldwell GW; Masucci JA
Electrophoresis; 1998 Mar; 19(3):448-54. PubMed ID: 9551800
[TBL] [Abstract][Full Text] [Related]
11. Serum albumin and lipoproteins as the quinidine binding molecules in normal human sera.
Nilsen OG
Biochem Pharmacol; 1976 May; 25(9):1007-12. PubMed ID: 178323
[No Abstract] [Full Text] [Related]
12. Uptake of the aromatic retinoids Ro 10-9359 (etretinate) and Ro 10-1670 (acitretin), its main metabolite, delivered to cultured human fibroblasts by serum proteins. Lack of evidence for perturbation of LDL catabolism.
Carillet V; Morlière P; Mazière JC; Hüppe G; Santus R; Dubertret L
Biochim Biophys Acta; 1990 Nov; 1055(2):102-6. PubMed ID: 2146974
[TBL] [Abstract][Full Text] [Related]
13. Preclinical anticancer activity of cryptophycin-8.
Corbett TH; Valeriote FA; Demchik L; Polin L; Panchapor C; Pugh S; White K; Knight J; Jones J; Jones L; LoRusso P; Foster B; Wiegand RA; Lisow L; Golakoti T; Heltzel CE; Ogino J; Patterson GM; Moore RE
J Exp Ther Oncol; 1996 Mar; 1(2):95-108. PubMed ID: 9414393
[TBL] [Abstract][Full Text] [Related]
14. In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines.
Wagner MM; Paul DC; Shih C; Jordan MA; Wilson L; Williams DC
Cancer Chemother Pharmacol; 1999; 43(2):115-25. PubMed ID: 9923816
[TBL] [Abstract][Full Text] [Related]
15. Melatonin high-affinity binding to alpha-1-acid glycoprotein in human serum.
Morin D; Simon N; Deprés-Brummer P; Lévi F; Tillement JP; Urien S
Pharmacology; 1997 May; 54(5):271-5. PubMed ID: 9380773
[TBL] [Abstract][Full Text] [Related]
16. Preferential binding of chlordecone to the protein and high density lipoprotein fractions of plasma from humans and other species.
Soine PJ; Blanke RV; Guzelian PS; Schwartz CC
J Toxicol Environ Health; 1982 Jan; 9(1):107-18. PubMed ID: 6174734
[TBL] [Abstract][Full Text] [Related]
17. Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends.
Panda D; DeLuca K; Williams D; Jordan MA; Wilson L
Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9313-8. PubMed ID: 9689077
[TBL] [Abstract][Full Text] [Related]
18. Effects of Cremophor EL on distribution of Taxol to serum lipoproteins.
Sykes E; Woodburn K; Decker D; Kessel D
Br J Cancer; 1994 Sep; 70(3):401-4. PubMed ID: 7915910
[TBL] [Abstract][Full Text] [Related]
19. Cryptophycins: a novel class of potent antimitotic antitumor depsipeptides.
Shih C; Teicher BA
Curr Pharm Des; 2001 Sep; 7(13):1259-76. PubMed ID: 11472266
[TBL] [Abstract][Full Text] [Related]
20. The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells.
Drew L; Fine RL; Do TN; Douglas GP; Petrylak DP
Clin Cancer Res; 2002 Dec; 8(12):3922-32. PubMed ID: 12473608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
